This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Sloan-Kettering Institute for Cancer Research, The Rockefeller University. Active years: 2016.
Company Filing History:
1 out of 518 
1 out of 751 
Years Active: 2016
Title: Sam Danishefsky: Innovator in Immunology
Introduction
Sam Danishefsky is a notable inventor based in Englewood, NJ (US). He has made significant contributions to the field of immunology, particularly through his innovative research and patents. His work focuses on the development of polypeptides that have the potential to treat various immune disorders.
Latest Patents
Danishefsky holds a patent for hDC-sign binding peptides. This patent describes polypeptides that bind to DC-SIGN and/or its homologues, along with methods for using such peptides in the treatment of various disorders. DC-SIGN and its homologues are receptors that bind IgG antibodies or Fc fragments, mediating the intravenous immunoglobulin (IVIG)-related reversal of inflammation associated with various immune disorders. He has 1 patent to his name.
Career Highlights
Throughout his career, Danishefsky has worked with prestigious institutions such as The Rockefeller University and the Sloan Kettering Institute for Cancer Research. His research has significantly advanced the understanding of immune responses and therapeutic interventions.
Collaborations
Danishefsky has collaborated with esteemed colleagues, including Jeffrey V. Ravetch and Andrew Pincetic. These collaborations have further enriched his research and contributed to the scientific community.
Conclusion
Sam Danishefsky's innovative work in immunology and his patent for hDC-sign binding peptides highlight his contributions to the field. His collaborations and career achievements reflect his dedication to advancing medical science.